Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Covidien Aims To Double Sales In Emerging Markets By 2017

This article was originally published in PharmAsia News

Executive Summary

Covidien plans to double its sales in emerging markets, primarily China and India, to $2 billion over the next five to six years, CEO Jose E. Almeida said during the firm's Sept. 8 investor meeting in New York

You may also be interested in...

Emerging Views On Emerging Markets: Goldman Sachs Global Healthcare Conference

PharmAsia News takes a closer look at presentations by Abbott, Covidien and Novartis.

Trends In MIS, Part I: Pushing Surgical Boundaries

The market for minimally invasive surgical products continues to grow, driven by increasing demand and advances in laparoscopic technologies and techniques. Medical device manufacturers are developing new and innovative endomechanical and energy devices, as well as improved camera systems, which are allowing surgeons to safely push surgical boundaries and expand the minimally invasive surgery (MIS) approach into more complex surgical procedures than ever before. From a market perspective, manufacturers are driving growth in the MIS product market by targeting underpenetrated and emerging markets, particularly in Asia and Latin America, and by focusing education, sales, and product development efforts on growing clinical areas with good potential for increasing MIS adoption.

Stryker Buys Concentric Medical To Enter Acute Ischemic Stroke Market

Stryker will gain access to the acute ischemic stroke market by acquiring privately held Concentric Medical for $135 million under a definitive agreement announced Aug. 31.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts